NEW YORK, October 24, 2022 (GLOBE NEWSWIRE) – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors in Bed Bath & Beyond Inc. (“Bed Bath & Beyond” or the “Company”) (NASDAQ: BBBY).

If you have purchased or otherwise acquired bed bath beyond common shares in between March 25, 2022 and August 18, 2022inclusive (the “Class Period”) and would like to discuss our investigation, please contact us via email [email protected] or by calling (646) 315-9003.

If you are a member of the proposed class, you can move the court by November 7, 2022 at the latest to serve as lead plaintiff for the alleged class. You do not have to seek lead plaintiff to participate in a possible recovery.

On March 6, 2022, Ryan Cohen (“Cohen”) sent a letter to the Board of Directors of Bed Bath & Beyond disclosing that his investment firm, RC Ventures LLC, owns a 9.8% interest in Bed Bath & Beyond. Cohen’s letter also criticized management for disappointing shareholder returns and continued underperformance, and put forward proposals to improve shareholder returns.

According to the complaint, on March 25, 2022, the company announced, among other things, that it had entered into a cooperation agreement with Cohen that gives him three board seats.

On August 16, 2022, RC Ventures LLC filed a Schedule 13D signed by Cohen with the SEC stating, “[a]As of the date of this document, RC Ventures directly beneficially owned 9,450,100 shares, including 1,670,100 shares underlying certain call options, representing approximately 11.8% of the outstanding shares.” According to the complaint, the 13D -Filing materially incorrect because, among other things, “Cohen filed Schedule 13D for the purpose of making it [a] Buying spree of BBBY shares, so that Cohen [could] stops selling its shares at an artificially inflated price[s]’ and ‘Cohen has actually sold most of its shares ‘as of the date of this document’ on August 16, 2022.’

According to the complaint also on…